Edition:
India

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

85.10GBp
23 May 2018
Change (% chg)

-1.10 (-1.28%)
Prev Close
86.20
Open
86.00
Day's High
86.45
Day's Low
84.70
Volume
1,436,081
Avg. Vol
6,094,783
52-wk High
127.22
52-wk Low
68.00

Latest Key Developments (Source: Significant Developments)

Sosei Says Does Not Intend To Make An Offer For Vectura
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Sosei Group Corp::STATEMENT RE PRESS COMMENT.CONFIRMS THAT IT DOES NOT INTEND TO MAKE AN OFFER FOR VECTURA.SOSEI WILL, EXCEPT WITH CONSENT OF UK PANEL ON TAKEOVERS AND MERGERS, BE BOUND BY RESTRICTIONS CONTAINED IN RULE 2.8 OF CODE.  Full Article

Vectura Says CFO Decided To Leave Group
Friday, 20 Apr 2018 

April 20 (Reuters) - Vectura Group PLC ::CHIEF FINANCIAL OFFICER AND EXECUTIVE DIRECTOR ANDREW DERODRA HAS DECIDED TO LEAVE GROUP.A SEARCH FOR HIS REPLACEMENT IS UNDERWAY AND GROUP WILL PROVIDE AN UPDATE ON HIS SUCCESSOR IN DUE COURSE.ANDREW WILL REMAIN IN HIS POSITION AT VECTURA AND ON BOARD UNTIL END OF JULY IN ORDER TO ENSURE A SMOOTH TRANSITION PROCESS.  Full Article

Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Vectura Group Plc ::FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS.FLUTIFORM PRODUCT SUPPLY REVENUE IN H2 2017 IS IN LINE WITH GUIDANCE PROVIDED.FLUTIFORMQ3 1 IN-MARKET NET SALES WERE EUR 47.8 MILLION 2 , UP 12% AT CONSTANT EXCHANGE RATES.ULTIBRO Q3 1 NET SALES OF $101 MILLION, WITH 18% GROWTH IN EUROPE YEAR-ON-YEAR.ROYALTIES FROM GSK ELLIPTA® PRODUCTS ACHIEVED £9 MILLION ANNUAL CAP IN Q3.WERE CURRENT EXCHANGE RATES TO CONTINUE THROUGH 2018, STERLING REPORTED REVENUES WOULD BE REDUCED BY APPROXIMATELY £5.0 MILLION.RESEARCH AND DEVELOPMENT COSTS IN 2018 ARE EXPECTED TO REDUCE TO £55 MILLION - £65 MILLION (PREVIOUS 2018 GUIDANCE: £65 MILLION - £75 MILLION).  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Update on Mundipharma's European Phase III trial of flutiform ® in COPD and latest flutiform ® in-market sales . Informed by its partner mundipharma that its phase iii trial of flutiform ® did not meet primary endpoint . Mundipharma is currently undertaking an analysis of trial's other endpoints .Mundipharma has indicated that primary endpoint result will not allow it to make a regulatory filing for COPD indication in Europe.  Full Article

Vectura says asthma drug misses primary endpoint in Phase III trial
Tuesday, 30 Aug 2016 

Vectura Group Plc : Has been informed by its partner Mundipharma that its phase III trial of flutiform® did not meet primary endpoint .Mundipharma is currently undertaking an analysis of trial's other endpoints but has indicated that primary endpoint result will not allow it to make a regulatory filing for copd indication in europe..  Full Article

Vectura initiates legal proceedings against GSK in the U.S.
Wednesday, 27 Jul 2016 

Vectura Group Plc : Vectura initiates legal proceedings against GlaxoSmithKline Plc (GSK) . Vectura has filed a patent infringement lawsuit against GSK claiming infringement of Vectura's U.S. patents in Delaware district court . Continues to remain open to finding a mutually acceptable solution in order to avoid costs and potential uncertainty over royalties that have, up to now, been subject to a cap of 13 mln stg per calendar year . Separate licence agreement with GSK relating to legacy Skyepharma dry powder formulation technology used in Ellipta products is unaffected .Despite notification from GSK, directors believe that revenues for current financial year ending December 2016 remain in line with current expectations.  Full Article

Vectura says Ablynx to exercise a license option on Fox device
Tuesday, 28 Jun 2016 

Vectura Group Plc :Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody.  Full Article

Skyepharma sayas High Court of Justice sanctions scheme on merger
Thursday, 9 Jun 2016 

Skyepharma Plc :High court of justice in england and wales made an order sanctioning scheme on merger with vectura.  Full Article